PURE Bioscience published a fiscal second-quarter 2026 financial results press release. In Q2 FY2026, net product sales rose 13.3% to USD 443,000, attributed to increased sales across its end-user network. Net loss in Q2 FY2026 was USD 0.79 million and net loss excluding share-based compensation was USD 727,000. For the six months ended Jan. 31, 2026, net product sales rose 21.6% to USD 1.15 million, while net loss narrowed 16% to USD 1.25 million on lower selling, general and administrative expenses, partly offset by higher interest expense tied to notes payable. PURE said it received USDA Biobased Product Certification for PURE Clean and expects to launch the product and fulfill pre-orders in fiscal Q3, while also pursuing new dairy applications, a dairy-farmer marketing campaign, and biomedical opportunities with Quip Laboratories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PURE Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603161605BIZWIRE_USPR_____20260316_BW962124) on March 16, 2026, and is solely responsible for the information contained therein.